The 2008 Pipeline Report - Pharmaceutical Executive


The 2008 Pipeline Report

Pharmaceutical Executive

Meningitis vaccines

A new Prevnar, plus new vaccines from Novartis and GSK

Established meningitis vaccines may lose market share to their successors beginning next year, when a fresh crop of multivalent vaccines is expected to hit the market.

Candidates by Wyeth and Novartis are expected to become at least $2 billion opportunities, according to Datamonitor's Holger Rovini.

Wyeth's Prevnar family of vaccines protect against pneumococcal serotypes that cause a variety of infections including blood infections and meningitis. The original Prevnar worked against seven serotypes. The new version, PNCRM13, also known as Prevnar 13v, targets those seven plus six more, including 19A, which is especially important in Asia. An additional indication is being sought for vaccinating the elderly. Rovini cited data that indicate vaccinating the very young can reduce the incidence of pneumococcal infections in the elderly, because vaccinated children do not infect their caregivers.

Synflorix, a 10-valent vaccine, excludes serotype 19A but adds non-typeable Haemophilus influenzae. The GSK drug could reach peak sales of $600–700 million.

Menveo could reap upwards of $2 billion for Novartis, according to Datamonitor. It competes with Sanofi-Pasteur's Menactra. Rovini notes that clinical data released by Novartis make Menveo appear superior, but the endpoints chosen may not prove any advantage over Menactra in terms of real-world benefits.


Breakthrough NSAIDS

PIlls can be slow and relatively ineffective (to say nothing of addictive), and self-injection is a problem for many patients. As a result, too many post-operative patients spend extra days in the hospital. Rox 888, Roxro's new nasally delivered formulation of the NSAID keterolac solves both of those problems. Rox 888 is fast acting and has proven as effective as intramuscular injections of keterolac in the control of abdominal and orthopedic post-surgical pain.

Holger Rovini
"This is a drug that can be easily administered in a home environment," says Neil Singla, MD, of Lotus Clinical Research in Pasadena, CA. "That's a huge advantage."

Meanwhile NiCox, a French company with an attractive nitric oxide–contributing technology has received positive Phase III results on its naproxcinod—which hit all its end points without detrimental effects to patient blood pressure. At a time when chronic pain meds are increasingly under fire for cardiac side effects, naproxcinod and the class of drugs coming up behind it could become major players.


blog comments powered by Disqus

Source: Pharmaceutical Executive,
Click here